Latest news with #Evotec
Globe and Mail
2 days ago
- Business
- Globe and Mail
Evotec SE Adjusts Revenue Guidance while Confirming Profit Guidance
HAMBURG, DE / ACCESS Newswire / July 21, 2025 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, Prime Standard, ISIN: DE 000 566480 9, WKN 566480; NASDAQ:EVO) announces that it has updated its revenue guidance for the fiscal year 2025. Guidance on R&D expenses and adjusted EBITDA remains unchanged. For the current fiscal year, the Company expects Group revenues in the range of €760-800m (previously: € 840 - 880 m; 2024: € 797.0 m); R&D expenditures are expected in a range of €40 - 50 m (unchanged; 2024: € 50.8 m); Adjusted EBITDA is expected to reach €30-50m (unchanged; 2024: € 22.6 m). The primary reasons for the refined guidance are a change in the revenue mix and significant cost savings in excess of initial targets set during the Priority Reset. Technology licensing - a key pillar of Evotec's strategic repositioning - is expected to make a stronger contribution. At the same time, the Shared R&D base business is expected to continue to operate in a challenging market environment in the second half of 2025. Group revenues were below expectations in H1 2025, while adjusted EBITDA was broadly in line with expectations. Actions are underway to transform the business towards sustainable profitable growth. - End of the ad hoc release - View the original press release on ACCESS Newswire
Associated Press
2 days ago
- Business
- Associated Press
Evotec Adjusts Revenue Guidance and Confirms Profit Guidance Anticipating a More Profitable Revenue Mix
HAMBURG, DE / ACCESS Newswire / July 21, 2025 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) today announced that it has updated its revenue guidance for the fiscal year 2025. R&D and adjusted EBITDA related guidance elements remain unaffected. For the current fiscal year, the Company expects revenues in the range of € 760 - 800 m (versus previously € 840 - 880 m; 2024: € 797.0 m); R&D expenditures are expected in a range of € 40 - 50 m (unchanged; 2024: € 50.8 m); Adjusted EBITDA 1 is expected to reach € 30 - 50 m (unchanged; 2024: € 22.6 m). Outlook 2028 remains unchanged with a targeted Group revenue CAGR 2024-2028 in a range of 8 - 12% and an expected adj. EBITDA margin above 20% by 2028. 1 Excluding potential costs related to the transformation program in 2025 CAGR: Compound annual growth rate In April, Evotec announced its new strategy for sustainable and profitable growth. A key element of this strategy is the refocused growth path, building on existing and new partnerships and further strengthened by leveraging its capabilities as a scalable technology and service provider. This also includes pivoting to a capex lighter model. The Company expects this value creation strategy to result in tangible results earlier than initially expected, driven by stronger than planned revenue contributions from high-margin technology license deals. After generating revenues below expectations in H1 2025, the Shared R&D base business is expected to continue to operate in a challenging market in the second half of 2025. Dr Christian Wojczewski, Chief Executive Officer of Evotec, said: 'Our strategy for sustainable and profitable growth is progressing as planned. Strong demand for higher margin businesses reflects the strength of our platforms and validates the decisions we've made around focus, partnerships, and capital efficiency. While some parts of our business continue to operate in a challenging market environment, the execution of our Priority Reset, and new strategy gives us confidence that we are well-positioned to deliver on our long-term ambitions.' The changing revenue mix is expected to positively influence the margin profile of the Evotec Group. In parallel, Evotec accelerated the implementation of its Priority Reset focused on ensuring sustainable profitable growth and right-sizing the business. The cost savings generated through these transformation efforts are now expected to exceed targets announced during the Q1 2025 results call on 06 May 2025. About Evotec SE Evotec is a life science company that is pioneering the future of drug discovery and development. By integrating breakthrough science with AI-driven innovation and advanced technologies, we accelerate the journey from concept to cure - faster, smarter, and with greater precision. Our expertise spans small molecules, biologics, cell therapies and associated modalities, supported by proprietary platforms such as Molecular Patient Databases, PanOmics and iPSC-based disease modeling. With flexible partnering models tailored to our customers' needs, we work with all Top 20 Pharma companies, over 800 biotechs, academic institutions, and healthcare stakeholders. Our offerings range from standalone services to fully integrated R&D programs and long-term strategic partnerships, combining scientific excellence with operational agility. Through Just - Evotec Biologics, we redefine biologics development and manufacturing to improve accessibility and affordability. With a strong portfolio of over 100 proprietary R&D assets, most of them being co-owned, we focus on key therapeutic areas including oncology, cardiovascular and metabolic diseases, neurology, and immunology. Evotec's global team of more than 4,800 experts operates from sites in Europe and the U.S., offering complementary technologies and services as synergistic centers of excellence. For additional information please go to and follow us on X/Twitter @Evotec and LinkedIn. Forward-looking statements This announcement contains forward-looking statements concerning future events, including the proposed offering and listing of Evotec's securities. Words such as 'anticipate,' 'believe,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'might,' 'plan,' 'potential,' 'should,' 'target,' 'would' and variations of such words and similar expressions are intended to identify forward-looking statements. Such statements include comments regarding Evotec's expectations for revenues, Group EBITDA and unpartnered R&D expenses. These forward-looking statements are based on the information available to, and the expectations and assumptions deemed reasonable by Evotec at the time these statements were made. No assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of Evotec. Evotec expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Evotec's expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based. For further information, please contact: Investor Relations Volker Braun EVP Head of Global Investor Relations & ESG [email protected] SOURCE: Evotec SE press release
Business Insider
05-07-2025
- Business
- Business Insider
Evotec (0IRF) Receives a Buy from RBC Capital
RBC Capital analyst Charles Weston maintained a Buy rating on Evotec on July 3 and set a price target of €11.90. The company's shares closed last Thursday at €7.16. Don't Miss TipRanks' Half-Year Sale Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. According to TipRanks, Weston is an analyst with an average return of -9.1% and a 31.58% success rate. Weston covers the Healthcare sector, focusing on stocks such as Evotec, Lonza Group Ltd, and Sartorius. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Evotec with a €10.07 average price target, which is a 40.60% upside from current levels. In a report released on June 26, Warburg Research also maintained a Buy rating on the stock with a €11.30 price target.
Yahoo
30-06-2025
- Business
- Yahoo
Evotec (EVO) Joins NURTuRE-AKI Consortium to Advance Kidney Injury Drug Discovery
Evotec SE (NASDAQ:EVO) is one of the 10 best healthcare penny stocks to buy according to analysts. On June 25, the company said it would participate in the NURTuRE-AKI consortium to investigate acute kidney injury (AKI) and advance drug discovery through multi-omics approaches. A research team in lab coats testing a new ImmunoPhage platform in a modern biotechnology lab. The NURTuRE-AKI consortium aims to establish the world's largest patient cohort database for AKI with twofold objectives: to enhance understanding of its molecular mechanisms and accelerate drug discovery. The consortium is supported by £4.7 million from industry partners, including Evotec, AstraZeneca (NASDAQ:AZN), and Nephrolyx GmbH, facilitated by Kidney Research UK. Professor Nick Selby, a key researcher, oversees the AKI research efforts within the NURTuRE initiative. Besides helping fund the consortium, Evotec will integrate the consortium's data into its proprietary platform. The company will also conduct state-of-the-art omics analyses to identify core biological mechanisms, molecular targets, and biomarkers for AKI. Ultimately, the partnership enables Evotec to conduct targeted drug discovery by leveraging molecular insights into the progression of AKI. Evotec SE (NASDAQ:EVO) is a German biotechnology company. It operates as a drug discovery and development partner for pharmaceutical and biotech firms worldwide. Its two main segments are Shared R&D, which offers integrated research services, and Just–Evotec Biologics, which provides biologics development and manufacturing. While we acknowledge the potential of EVO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: Goldman Sachs Energy Stocks: 10 Stocks to Buy and 10 Best AI Stocks to Buy According to Billionaire David Tepper. Disclosure: None.
Associated Press
26-05-2025
- Business
- Associated Press
Chair of Sernova Biotherapeutics Resigns
LONDON, Ontario and BOSTON, May 26, 2025 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics, (TSX: SVA) (OTCQB: SEOVF) (FSE/XETRA: PSH), a leading regenerative medicine company focused on developing its Cell Pouch Bio-hybrid Organ as a functional cure for type 1 diabetes (T1D), today announced the resignation of its Chair. Mr. Ross Haghighat tendered his resignation on May 24th and it was accepted by the Sernova Board. The Board of Directors of Sernova thanks Ross for his service as a trusted leader and sincerely wishes him luck in the future. ABOUT SERNOVA BIOTHERAPEUTICS Sernova Biotherapeutics is a clinical-stage company developing regenerative medicine therapeutics combining its Cell Pouch with human donor cells or stem-cell derived islet like clusters in collaboration with Evotec to create Bio-hybrid Organs to treat T1D. A Bio-hybrid Organ is comprised of non-biomaterials, such as the Cell Pouch, integrated with living tissues to restore or enhance the function of a compromised organ. This innovative approach aims to deliver a potentially revolutionary treatment for patients with chronic diseases, initially focusing on T1D and thyroid disorders. FOR FURTHER INFORMATION, PLEASE CONTACT: David Burke VP, Investor Relations (917) 751-5713 Email: [email protected] Website: The TSX has not reviewed this news release and does not accept responsibility for the accuracy or adequacy of this news release.
